With growing public interest in GLP-1 medications such as semaglutide (Ozempic®, Rybelsus®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound®) for diabetes management and weight loss, Canadians are increasingly encountering these products through online sellers, social media ads, and unauthorized retailers.
Unfortunately, not all GLP-1 products being sold in Canada are legitimate or safe.
(more…)
We want to inform our patients and the community about an important update regarding Saxenda® (liraglutide injection).
Saxenda® has been discontinued — the manufacturer has ended production and commercial availability of the medication. This decision was not due to any safety or quality concerns with the medication.
(more…)
The global demand for medications like Ozempic (semaglutide) and other GLP-1 receptor agonists has transformed the treatment landscape for type 2 diabetes and obesity. These medications have helped many patients achieve better blood sugar control and, when appropriate, support weight management.
(more…)GLP-1 receptor agonist medications have become some of the most widely prescribed drugs in Canada. Ozempic, Wegovy, Mounjaro, and now generic semaglutide are reshaping how clinicians and patients approach both type 2 diabetes and chronic weight management. If you are in Ottawa and trying to understand how to access one of these medications, this guide covers what you need to know.
(more…)
For years, the cost of Ozempic (semaglutide) has been a barrier for many Canadians managing type 2 diabetes. At $250 to $310 per month, the brand-name medication — despite its clinical effectiveness — was simply out of reach for patients without comprehensive drug coverage. That changed in the spring of 2026.
(more…)
Significant weight loss—whether achieved through bariatric surgery or newer pharmacologic therapies such as GLP-1 receptor agonists—offers substantial benefits for cardiometabolic health. However, emerging evidence shows that rapid weight reduction can paradoxically lead to new dermatological conditions, particularly when nutritional deficiencies are not proactively identified and managed.
(more…)
Weight-loss medications such as Wegovy and Mounjaro have transformed obesity management. By targeting hormonal pathways involved in appetite regulation—particularly GLP-1 receptors—these therapies help patients feel fuller sooner and reduce caloric intake in a way that previously felt unattainable.
(more…)
Health Canada has expanded the approved use of Ozempic (semaglutide injection) to help reduce the risk of serious cardiovascular complications in adults living with type 2 diabetes.
(more…)
GLP-1 agonist medications have become an important option in the treatment of obesity, diabetes, and metabolic health. In recent years, growing awareness, new research, and changes in medication availability have raised many questions for patients considering or already using these therapies.
(more…)